Susan Knox

Clinical Focus

• Cancer> Radiation Oncology
• Cancer> Radiation Oncology> Radiation Therapy
• Radiation Oncology
• Radiation Therapy

Administrative Appointments

• Associate Professor (University Tenure Line), Stanford Univ. Sch. of Medicine (1997 - 2008)
• Assistant Professor (University Tenure Line), Stanford Univ. Sch. of Medicine (1990 - 1997)
• Assistant Dean for Medical Student Advising, Stanford Univ. Sch. of Medicine (2002 - 2008)
• Member, Oncological Sciences Study Section Boundaries Team (2001 - 2001)
• Member, Clinical Oncology Study Section (2001 - 2004)
View All 20administrative appointments of Susan Knox

Honors and Awards

• Clinical Oncology Career Development Award, American Cancer Society (1991-94)
• Lazard Faculty Scholar, Lazard Faculty (1992-93)
• Board of Governors, Stanford Medical Alumni Association (2000-2008)
• Charles F. Kettering Selection Committee, General Motors Cancer Research Foundation (2000-2002)
• Elected Councilor Medicine, Radiation Research Society (2003)

Professional Education

Postdoctoral Advisees

Junqiang Tian

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Immunology
• Radiation Oncology
• Molecular and Genetic Medicine

Web Site Links

• http://www.stanford.edu/group/RIT

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

- Radioimmunotherapy (RIT) and Systemically Targeted Radiation Therapy
- Low Dose Rate Effects
- Radioprotective Agents, Growth Factors/Receptors
- Oncogenes, Apoptosis & Radiosensitivity
- Apoptosis and Signal Transduction Pathways
- Effects of Radiation on the Immune Response
- Biological Response Modifiers and Novel Targeted Radiosensitizers
- Non-Hodgkin's Lymphomas
- Mycosis Fungoides
- Breast and Prostate Cancer
- Radiation as a component of Tumor Vaccine Strategies

Clinical Trials

• Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma Recruiting
• Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma Recruiting
• Study of Bexxar Combined with External Beam Radiation Therapy for Patients with Relapsed, Bulky Non-Hodgkin's Lymphoma Recruiting
• Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma Completed
• Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas No longer recruiting

Publications

• Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Ning S, Knox SJ, Harsh GR, Culler MD, Katznelson L. Endocr Relat Cancer. 2009; 16 (3): 1045-55
• (131)I-Tositumomab (Bexxar(R)) vs. (90)Y-Ibritumomab (Zevalin(R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. Iagaru A, Mittra ES, Ganjoo K, Knox SJ, Goris ML. Mol Imaging Biol. 2009
• Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ. Int J Radiat Oncol Biol Phys. 2008; 72 (3): 935-40
• Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Mol Cancer Ther. 2008; 7 (6): 1569-78
• Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Cancer. 2007; 110 (3): 477-88